Jeanne M Regnante1, Nicole A Richie2, Lola Fashoyin-Aje3, Michelle Vichnin4, Marvella Ford5, Upal Basu Roy6, Kenneth Turner7, Laura Lee Hall1, Evelyn Gonzalez8, Nestor Esnaola9, Luther T Clark4, Homer C Adams10, Olatunji B Alese11, Keerthi Gogineni11, Lorna McNeill12, Daniel Petereit13, Ify Sargeant14, Julie Dang15, Coleman Obasaju16, Quita Highsmith2, Simon Craddock Lee17, Spencer C Hoover18, Erin L Williams17, Moon S Chen15. 1. 1 Sustainable Healthy Communities, Washington, DC. 2. 2 Genentech, South San Francisco, CA. 3. 3 US Food and Drug Administration, Bethesda, MD. 4. 4 Merck & Co, Kenilworth, NJ. 5. 5 Hollings Cancer Center, Medical University of South Carolina, Charleston, SC. 6. 6 LUNGevity Foundation, Chicago, IL. 7. 7 Johnson & Johnson, New Brunswick, NJ. 8. 8 Fox Chase Cancer Center, Philadelphia, PA. 9. 9 Houston Methodist Hospital, Houston, TX. 10. 10 Janssen Research & Development, Raritan, NJ. 11. 11 Winship Cancer Institute of Emory University, Atlanta, GA. 12. 12 University of Texas MD Anderson Cancer Center, Houston, TX. 13. 13 Rapid City Regional Cancer Care Institute, Rapid City, SD. 14. 14 Ismedica, Wrinehill, United Kingdom. 15. 15 University of California, Davis Comprehensive Cancer Center, Davis, CA. 16. 16 Eli Lilly, Indianapolis, IN. 17. 17 University of Texas Southwestern Medical Center, Dallas, TX. 18. 18 Henry Ford Cancer Institute, Detroit, MI.
Abstract
PURPOSE: Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproportionately low despite a high prevalence of certain cancers in REMG populations. We aimed to identify notable practices used by leading US cancer centers that facilitate REMG participation in cancer trials. METHODS: The National Minority Quality Forum and Sustainable Healthy Communities Diverse Cancer Communities Working Group developed criteria by which to identify eligible US cancer centers-REMGs comprise 10% or more of the catchment area; a 10% to 50% yearly accrual rate of REMGs in cancer trials; and the presence of formal community outreach and diversity enrollment programs. Cancer center leaders were interviewed to ascertain notable practices that facilitate REMG accrual in clinical trials. RESULTS: Eight cancer centers that met the Communities Working Group criteria were invited to participate in in-depth interviews. Notable strategies for increased REMG accrual to cancer trials were reported across five broad themes: commitment and center leadership, investigator training and mentoring, community engagement, patient engagement, and operational practices. Specific notable practices included increased engagement of health care professionals, the presence of formal processes for obtaining REMG patient/caregiver input on research projects, and engagement of community groups to drive REMG participation. Centers also reported an increase in the allocation of resources to improving health disparities and increased dedication of research staff to REMG engagement. CONCLUSION: We have identified notable practices that facilitate increased participation of REMGs in cancer trials. Wide implementation of such strategies across cancer centers is essential to ensure that all populations benefit from advances in an era of increasingly personalized treatment of cancer.
PURPOSE: Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproportionately low despite a high prevalence of certain cancers in REMG populations. We aimed to identify notable practices used by leading US cancer centers that facilitate REMG participation in cancer trials. METHODS: The National Minority Quality Forum and Sustainable Healthy Communities Diverse Cancer Communities Working Group developed criteria by which to identify eligible US cancer centers-REMGs comprise 10% or more of the catchment area; a 10% to 50% yearly accrual rate of REMGs in cancer trials; and the presence of formal community outreach and diversity enrollment programs. Cancer center leaders were interviewed to ascertain notable practices that facilitate REMG accrual in clinical trials. RESULTS: Eight cancer centers that met the Communities Working Group criteria were invited to participate in in-depth interviews. Notable strategies for increased REMG accrual to cancer trials were reported across five broad themes: commitment and center leadership, investigator training and mentoring, community engagement, patient engagement, and operational practices. Specific notable practices included increased engagement of health care professionals, the presence of formal processes for obtaining REMG patient/caregiver input on research projects, and engagement of community groups to drive REMG participation. Centers also reported an increase in the allocation of resources to improving health disparities and increased dedication of research staff to REMG engagement. CONCLUSION: We have identified notable practices that facilitate increased participation of REMGs in cancer trials. Wide implementation of such strategies across cancer centers is essential to ensure that all populations benefit from advances in an era of increasingly personalized treatment of cancer.
Authors: Helen E Heslop; Edward A Stadtmauer; John E Levine; Karen K Ballen; Yi-Bin Chen; Amy E DeZern; Mary Eapen; Mehdi Hamadani; Betty K Hamilton; Parameswaran Hari; Richard J Jones; Brent R Logan; Leslie S Kean; Eric S Leifer; Frederick L Locke; Richard T Maziarz; Eneida R Nemecek; Marcelo Pasquini; Rachel Phelan; Marcie L Riches; Bronwen E Shaw; Mark C Walters; Amy Foley; Steven M Devine; Mary M Horowitz Journal: Transplant Cell Ther Date: 2021-08-27
Authors: Soumya J Niranjan; Jennifer A Wenzel; Michelle Y Martin; Mona N Fouad; Selwyn M Vickers; Badrinath R Konety; Raegan W Durant Journal: JCO Oncol Pract Date: 2021-05
Authors: Julie A Schneider; Yutao Gong; Kirsten B Goldberg; Paul G Kluetz; Marc R Theoret; Laleh Amiri-Kordestani; Julia A Beaver; Lola Fashoyin-Aje; Nicole J Gormley; Adnan A Jaigirdar; Steven J Lemery; Pallavi S Mishra-Kalyani; Gregory H Reaman; Donna R Rivera; Wendy S Rubinstein; Harpreet Singh; Rajeshwari Sridhara; Richard Pazdur Journal: Clin Cancer Res Date: 2021-10-01 Impact factor: 12.531
Authors: Karen M Winkfield; Jeanne M Regnante; Ellen Miller-Sonet; Evelyn T González; Karen M Freund; Patricia M Doykos Journal: JCO Oncol Pract Date: 2021-01-18
Authors: Jennifer A H Bell; Mary T Kelly; Karen Gelmon; Kim Chi; Anita Ho; Patricia Rodney; Lynda G Balneaves Journal: Cancer Med Date: 2020-04-20 Impact factor: 4.452
Authors: Jordan M Neil; Yuchiao Chang; Brett Goshe; Nancy Rigotti; Irina Gonzalez; Saif Hawari; Lauren Ballini; Jennifer S Haas; Caylin Marotta; Amy Wint; Kim Harris; Sydney Crute; Efren Flores; Elyse R Park Journal: JMIR Form Res Date: 2021-06-30